See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
First Trust NASDAQ Pharmaceuticals ETF (FTXH) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
First Trust NASDAQ Pharmaceuticals ETF (FTXH) - free report >>
Image: Bigstock
Nasdaq Pharmaceuticals ETF (FTXH) Hits a 52-Week High
For investors looking for momentum, First Trust Nasdaq Pharmaceuticals ETF (FTXH - Free Report) is probably a suitable pick. The fund just hit a 52-week high and is up 53.7% from its 52-week low price of $16.28/share.
Let’s take a look at the fund and its near-term outlook to gain an insight into where it might be headed:
FTXH in Focus
The fund seeks investment results that correspond generally to the price and yield, before fees and expenses, of the Nasdaq US Smart Pharmaceuticals Index. It has AUM of $15.5 million and charges expense ratio of 60 basis points.
Why the Move?
The coronavirus outbreak continues to aggravate in the United States and globally. In fact, the United Kingdom is seeing a rise in infections and the government is considering another national lockdown to control the situation, per a CNBC article. In such a scenario, all eyes are on the progress in the development of a coronavirus vaccine, treatment or test. Along with positive developments in coronavirus vaccine and antibodies, there have been news of mergers and acquisitions in the sector as well. This is making funds like FTXH an attractive investment option.
More Gains Ahead?
It seems like the fund will remain strong, with a positive weighted alpha of 14.90, which gives cues of further rally.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free>>